Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients

被引：0
|
作者：
Ninh M. La-Beck
Beth A. Zamboni
Alberto Gabizon
Hilary Schmeeda
Michael Amantea
Paola A. Gehrig
William C. Zamboni
机构：
[1] University of North Carolina at Chapel Hill,UNC Eshelman School of Pharmacy
[2] Texas Tech University Health Sciences Center,Center for Immunotherapeutic Research and Department of Pharmacy Practice, School of Pharmacy
[3] Carlow University,Department of Mathematics
[4] Shaare Zedek Medical Center and Hebrew University-School of Medicine,Department of Oncology
[5] Pfizer,Department of Clinical Pharmacology
[6] Inc.,Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, UNC School of Medicine
[7] University of North Carolina at Chapel Hill,Molecular Therapeutics, Lineberger Comprehensive Cancer Center
[8] University of North Carolina at Chapel Hill,Institute for Pharmacogenomics and Individualized Therapy
[9] University of North Carolina at Chapel Hill,Carolina Center of Cancer Nanotechnology Excellence
[10] University of North Carolina at Chapel Hill,Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy
[11] University of North Carolina at Chapel Hill,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Doxil; Liposomal; Pharmacokinetics; Variability; Monocytes; Reticuloendothelial system; Doxorubicin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：43 / 50
页数：7
相关论文
共 50 条
  • [1] Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients
    La-Beck, Ninh M.
    Zamboni, Beth A.
    Gabizon, Alberto
    Schmeeda, Hilary
    Amantea, Michael
    Gehrig, Paola A.
    Zamboni, William C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (01) : 43 - 50
  • [2] Pharmacokinetics of the intraperitoneal nanoparticle pegylated liposomal doxorubicin in patients with peritoneal metastases
    Sugarbaker, Paul H.
    Stuart, O. Anthony
    EJSO, 2021, 47 (01): : 108 - 114
  • [3] Multiple injections of pegylated liposomal doxorubicin: Pharmacokinetics and therapeutic activity
    Charrois, GJR
    Allen, TM
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 306 (03): : 1058 - 1067
  • [4] Pharmacokinetics of pegylated liposomal doxorubicin - Review of animal and human studies
    Gabizon, A
    Shmeeda, H
    Barenholz, Y
    CLINICAL PHARMACOKINETICS, 2003, 42 (05) : 419 - 436
  • [5] Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
    Wu, Huali
    Infante, Jeffrey R.
    Keedy, Vicki L.
    Jones, Suzanne F.
    Chan, Emily
    Bendell, Johanna C.
    Lee, Wooin
    Kirschbrown, Whitney P.
    Zamboni, Beth A.
    Ikeda, Satoshi
    Kodaira, Hiroshi
    Rothenberg, Mace L.
    Burris, Howard A., III
    Zamboni, William C.
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2015, 10 : 1201 - 1209
  • [6] Investigation of factors affecting in vitro doxorubicin release from PEGylated liposomal doxorubicin for the development of in vitro release testing conditions
    Shibata, Hiroko
    Izutsu, Ken-ichi
    Yomota, Chikako
    Okuda, Haruhiro
    Goda, Yukihiro
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2015, 41 (08) : 1376 - 1386
  • [7] Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel
    Evangelos Briasoulis
    Vasilis Karavasilis
    Eleftheria Tzamakou
    Dimitra Rammou
    Kali Soulti
    Christina Piperidou
    Nicholas Pavlidis
    Cancer Chemotherapy and Pharmacology, 2004, 53 : 452 - 457
  • [8] Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel
    Briasoulis, E
    Karavasilis, V
    Tzamakou, E
    Rammou, D
    Soulti, K
    Piperidou, C
    Pavlidis, N
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (05) : 452 - 457
  • [9] Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer
    Anders, Carey K.
    Adamo, Barbara
    Karginova, Olga
    Deal, Allison M.
    Rawal, Sumit
    Darr, David
    Schorzman, Allison
    Santos, Charlene
    Bash, Ryan
    Kafri, Tal
    Carey, Lisa
    Miller, C. Ryan
    Perou, Charles M.
    Sharpless, Norman
    Zamboni, William C.
    PLOS ONE, 2013, 8 (05):
  • [10] Pharmacokinetics and its relation to toxicity of pegylated-liposomal doxorubicin in chinese patients with breast tumours
    Xu, L.
    Wang, W.
    Sheng, Y. C.
    Zheng, Q. S.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2010, 35 (05) : 593 - 601
12345